PPAR Research / 2013 / Article / Tab 4

Clinical Study

Dual PPAR α/γ Agonism Normalizes Lipoprotein Profile of Renal Dyslipidemia

Table 4

Plasma concentrations of lipoprotein subclasses (mg/dL) in patients with chronic renal insufficiency (n = 23) and healthy reference subjects (n = 17) at start and end of treatment with 1 mg tesaglitazar o.d. Mean and standard (in parenthesis).

CKD patientsHealthy reference group
At entryAfter 6 weeksEstimated changeAt entryAfter 6 weeksEstimated change

Lp-A-I36 (5)40 (6)+11%**37 (7)37 (7)−1%
Lp-A-I : A-II105 (12)114 (17)+8%**108 (20)117 (15)+10%
Lp-B79 (18)67 (19)−17%***67 (11)58 (10)−13%**
Lp-B : C10 (8) 7 (3)−26%*6 (2)5 (2) −19%
Lp-B : E + Lp-B : C : E 20 (8)14 (6)−28%**13 (6)10 (4)−11%
Lp-A-II : B : C : D : E17 (7)16 (9)−9%20 (9)15 (8)−29%*

P < 0.05, **P < 0.01, and ***P < 0.001 with group comparison between baseline and after 6 weeks of treatment.